-
Science & Research
-
Critical Path Initiative
About Critical Path
The Critical Path Initiative (CPI) is FDA's national strategy for transforming the way FDA-regulated products are developed, evaluated, manufactured, and used. More
Critical Path Opportunities Reports
- Critical Path Annual Report 2008
- FDA's Sentinel Initiative
- Critical Path Opportunities Initiated During 2007
- Critical Path Opportunities for Generic Drugs
- More
Faces Behind Critical Path
- Collaboration cornerstone of CPI... Interview with Dr. Rachel Behrman
- Making Medical Products Better, Faster, and Cheaper
- Interview on Warfarin
- Janet Woodcock Commentary on Critical Path
- More
Articles and Presentations
- FDA's Proactive Role in the Development of an Artificial Pancreas for Treating Diabetes Mellitus
- Developing new drugs for the treatment of drug resistant tuberculosis: a regulatory perspective
- Bioinformatics Modernization and the Critical Path to Improved Benefit-Risk Assessment of Drugs
- More
Spotlight on CPI Projects
- Dual Antiplatelet Therapy (DAPT) Trial - new
- Clinical Trials Transformation Initiative
- Drug Discovery Today Interviews CTTI
- CDRH Medical Device Fellowship Program
- News on Genetic Basis of Adverse Events
- MedWatchPlus Update
- More
Multimedia
Contact Us
- 301-827-1512
- 301-443-9718
- FDA Critical Path Program
FDA's Office of Critical Path Programs
Dr. Rachel Behrman, Director
Dr. Leonard Sacks, Deputy Director
-
-
-